QQ客服 官方微博 反馈留言

	LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway
	Zhu, Qiong-Ni; Wang, Guo*; Guo, Ying; Peng, Yan; Zhang, Rui; Deng, Jun-Li; Li, Zhi-Xing; Zhu, Yuan-Shan*
刊名	Oncotarget
	2017
卷号	8期号:54页码:91990-92003
关键词	ABCB1 CUL4A breast cancer chemoresistance lncRNA H19
ISSN号	1949-2553
DOI	10.18632/oncotarget.21121
URL标识	查看原文
WOS记录号	WOS:000414606800015
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3328914
专题	中南大学
作者单位	1.[Zhu, Qiong-Ni 2.Peng, Yan 3.Wang, Guo 4.Zhu, YS 5.Deng, Jun-Li 6.Zhu, Yuan-Shan 7.Guo, Ying 8.Li, Zhi-Xing 9.Zhang, Rui] Cent S Univ, Inst Clin Pharmacol, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Hunan, Peoples R China.
推荐引用方式 GB/T 7714	Zhu, Qiong-Ni,Wang, Guo*,Guo, Ying,et al. LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway[J]. Oncotarget,2017,8(54):91990-92003.
APA	Zhu, Qiong-Ni.,Wang, Guo*.,Guo, Ying.,Peng, Yan.,Zhang, Rui.,...&Zhu, Yuan-Shan*.(2017).LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway.Oncotarget,8(54),91990-92003.
MLA	Zhu, Qiong-Ni,et al."LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway".Oncotarget 8.54(2017):91990-92003.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。